BOSTON--(BUSINESS WIRE)--Manifold Bio, a platform therapeutics company pioneering AI-guided drug discovery coupled with direct-to-vivo measurement, today announced a strategic research collaboration and license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY). The partnership will apply Manifold's proprietary tissue-targeting shuttle portfolio and mDesign AI-driven in vivo discovery engine to create multiple next-generation BBB shuttles for the treatment of neurological and neurodegenerative d. ...